文献速递耳科与耳神经头颈外科

2型神经纤维瘤病中人工耳蜗与听觉脑干植入的听力康复效果

Cochlear implantation and auditory brainstem implantation in neurofibromatosis type 2.
PubMed 文献 · Laryngoscope · 2018-03-24

该回顾性病例系列纳入10例同时接受人工耳蜗植入和听觉脑干植入的2型神经纤维瘤病(NF2)患者,分别评估两种装置的言语识别效果。结果显示,耳蜗神经完整时人工耳蜗植入可有效康复听力,但部分患者因肿瘤生长或治疗出现效果下降;听觉脑干植入功能稳定但峰值表现通常低于人工耳蜗。

要点

  • 耳蜗神经完整时,人工耳蜗植入可作为NF2听力康复的有效策略。
  • 部分患者人工耳蜗效果可下降至不可用水平,与肿瘤生长或治疗相关。
  • 听觉脑干植入功能随时间稳定,但峰值表现通常低于人工耳蜗。

核心结论

  • 耳蜗神经完整时,人工耳蜗植入对NF2听力康复有效,但相当比例患者因肿瘤生长或治疗出现效果下降。
  • 听觉脑干植入仍是NF2手术听力康复的标准选择,但其峰值表现通常低于人工耳蜗。

研究设计与样本

  • 回顾性病例系列,纳入10例同时接受人工耳蜗植入和听觉脑干植入的NF2患者。
  • 分别对人工耳蜗和听觉脑干植入进行言语测试,取末次随访时Iowa元音与辅音、NU-CHIPS及CUNY句子得分。

主要发现

  • 人工耳蜗植入时平均年龄37岁,听觉脑干植入时平均年龄40岁(P = .790,t检验)。
  • 10例中9例人工耳蜗与听觉脑干植入位于对侧,1例两种装置位于同侧。
  • 植入耳平均耳聋病程在两种植入中均为4.3年(P = .491,t检验),随访范围1至28年。
  • 人工耳蜗NU-CHIPS得分为32%至100%,声+唇读CUNY得分为56%至100%;4例患者人工耳蜗功能最终下降至不可用水平。
  • 听觉脑干植入NU-CHIPS得分为40%至80%,声+唇读CUNY得分为38%至94%;听觉脑干植入功能随时间无显著下降。

临床怎么用

  • 对NF2患者评估听力康复时,若耳蜗神经完整可考虑人工耳蜗植入,但需告知功能可能因肿瘤生长或治疗而下降。
  • 听觉脑干植入可作为NF2手术听力康复的标准选项,应告知其峰值表现通常低于人工耳蜗。

局限性

  • 回顾性病例系列,样本量10例,证据等级为4级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To report a series of patients with neurofibromatosis type 2 (NF2), where each patient underwent both cochlear implantation and auditory brainstem implantation for hearing rehabilitation, and to discuss factors influencing respective implant success. STUDY DESIGN: Retrospective case series. METHODS: Ten NF2 patients with both cochlear implantations and auditory brainstem implantations were retrospectively reviewed. Speech testing for auditory brainstem implants (ABIs) and cochlear implants (CIs) was performed separately. Scores at last follow-up were obtained for Iowa vowels and consonants, Northwestern University Children's Perception of Speech (NU-CHIPS), and City University of New York (CUNY) sentences. RESULTS: Mean age at time of implant was 37 years for cochlear implantation and 40 years for auditory brainstem implantation (P = .790, t test). Nine of 10 patients had a CI and ABI on contralateral sides, and one had both devices on the same side. Mean duration of deafness in the implanted ear was 4.3 years for both cochlear implantation and auditory brainstem implantation (P = .491, t test). Follow-up range was 1 to 28 years. CI performance on NU-CHIPS was 32% to 100%, and sound + lip-reading CUNY was 56% to 100%. Four patients experienced an eventual decline in CI function to unusable levels. ABI performance on NU-CHIPS was 40% to 80%, and sound + lip-reading CUNY was 38% to 94%. There was no notable decline in ABI function over time. CONCLUSIONS: If the cochlear nerve is intact, cochlear implantation can be an effective strategy for hearing rehabilitation in NF2. However, a significant proportion experience a decline in CI performance related to growing vestibular schwannoma or tumor treatment. Auditory brainstem implantation remains the standard option for surgical hearing rehabilitation in NF2, but peak performance is generally lower than that achievable with cochlear implantation. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:2163-2169, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Peng KA, Lorenz MB, Otto SR, et al. Cochlear implantation and auditory brainstem implantation in neurofibromatosis type 2. Laryngoscope. 2018. PMID: 29573425. doi:10.1002/lary.27181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。